Skip to main content
SpringerLink
Log in

Effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients with RRM1 low protein expression

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Objective

The aim of this study was to observe the efficacy of gemcitabine combined with cisplatin (GP) in advanced non-small cell lung cancer (NSCLC) patients with low expression of ribonucleotide reductase 1 (RRM1) protein using immunohistochemistry.

Methods

RRM1 protein expression in tumor tissue was detected by streptavidin-peroxidase (SP) method of immunohistochemistry. GP regimen (gemcitabine 1000–1250 mg d1, d8, cisplatin 75 mg/m2) was given to advanced NSCLC patients with low expression of RRM1 protein.

Results

In the total of 40 patients, these patients with RRM1 low expression performing GP chemotherapy had a good response rate, the objective response rate (ORR) was 47.5% (95% CI, 32.02%–62.98%), and the disease control rate (DCR) was 72.5% (95 % CI, 65.44%–79.56%). ORR is 45.45% (5/11) in the squamous cell carcinoma patients while 48.15% (13/27) in the adenocarcinoma patients.

Conclusion

Superior ORR and DCR were found in advanced NSCLC patients with low expression of RRM1 protein expression performing GP regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346: 92–98.

    Article  PubMed  CAS  Google Scholar 

  2. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-smallcell lung cancer: Four-arm cooperative study in Japan. Ann Oncol, 2007, 18: 317–323.

    Article  PubMed  CAS  Google Scholar 

  3. Li HM, Li HX, Liu KW, et al. Three chemotherapy regimens including cisplatin for advanced non-small cell lung caner. J Shandong Univ (Chinese), 2007, 45: 499–502.

    Google Scholar 

  4. Cui TJ, Liu ZH, Chen Z, et al. Comparisons among four chemotherapeutic regimens for advanced non-small cell lung cancer. J Oncol (Chinese), 2006, 12: 136–138.

    Google Scholar 

  5. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol, 2006, 17: 1818–1825.

    Article  PubMed  CAS  Google Scholar 

  6. Boukovinas I, Papadaki C, Mendez P, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One, 2008, 3: e3695.

    Article  PubMed  Google Scholar 

  7. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol, 2007, 25: 2741–2746.

    Article  PubMed  CAS  Google Scholar 

  8. Reynolds C, Obasaju C, Schell MJ, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol, 2009, 27: 5808–5815.

    Article  PubMed  CAS  Google Scholar 

  9. Bepler G, Olaussen KA, Vataire AL, et al. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol, 2011, 178: 69–78.

    Article  PubMed  Google Scholar 

  10. Kassis ES, Vaporciyan AA, Swisher SG, et al. Application of the revised lung cancer staging system (IASLC staging project) to a cancer center population. J Thorac Cardiovasc Surg, 2009, 138: 412–418.

    Article  PubMed  Google Scholar 

  11. Spiellmen M, Lombart Cussal, Kallas, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology, 2001, 60: 303–307.

    Article  Google Scholar 

  12. Kim SO, Jeong JY, Kim MR, et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res, 2008, 14: 3083–3088.

    Article  PubMed  CAS  Google Scholar 

  13. Li SW, Li YJ, Hu YQ, et al. GP and NP regimen treated in advanced non-small cell lung cancer. Chin J Lung Cancer (Chinese), 2006, 9: 379–380.

    Google Scholar 

  14. Luo FS, Shi HB, Li WH. Obserbvation of Gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer. J Qiqihar Med Coll (Chinese), 2006, 27: 929–929.

    Google Scholar 

  15. Lee JJ, Maeng CH, Baek SK, et al. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer, 2010, 70: 205–210.

    Article  PubMed  Google Scholar 

  16. Zhu J, Zhang J, Zhou CC, et al. Curative effect of gemcitabine combined with platinum drugs on treatment of advanced squamous carcinoma and carcinoma and adenocarcinoma of lung. J Tongji Univ (Chinese), 2009, 30: 77–80.

    Google Scholar 

  17. Chen K, Li YJ, Zhang CF, et al. Efficacy of domestic gemcitabine combined with cisplatin in treatment of advanced squamous carcinoma and adenocarcinoma of lung. Chin J Clin Oncol Rehabil (Chinese), 2010, 17: 366–369.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiothoracic Surgery, Guangzhou Institution of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical College, Guanzhou, 510120, China

    Meiling Zhao, Haihong Yang, Jun liu & Jianxing He

  2. Department of Radiology, The First Affiliated Hospital of Guangzhou Medical College, Guanzhou, 510120, China

    Yubao Guan

  3. Department of Pathology, The First Affiliated Hospital of Guangzhou Medical College, Guanzhou, 510120, China

    Mingchong Mo & Enyun Lin

Authors
  1. Meiling Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haihong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yubao Guan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mingchong Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Enyun Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jianxing He
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianxing He.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhao, M., Yang, H., liu, J. et al. Effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients with RRM1 low protein expression. Chin. -Ger. J. Clin. Oncol. 10, 687–691 (2011). https://doi.org/10.1007/s10330-011-0874-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-011-0874-8

Key words

Search

Navigation